Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics plc

20 Feb 2013 12:54

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics plc

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics plc

PR Newswire

London, February 20

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A

PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/ Aberforth Partners LLP, ondealings are being disclosed:

behalf of discretionary clients.(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):The naming of nominee or vehicle companies isinsufficient

(c) Name of offeror/offeree in relation to Ark Therapeutics Group plcwhose relevant securities this form relates:

Use a separate form for each offeror/offeree(d) If an exempt fund manager connected withan offeror/offeree, state this and specifyidentity of offeror/offeree:(e) Date position held/dealing undertaken: 19 February 2013(f) Has the discloser previously disclosed, or Y/N NOare they today disclosing, under the Code in

respect of any other party to this offer? If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror orofferee to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares Interests Short positions Number % Number %(1) Relevant securities owned 20,580,092 9.83 0 0.0and/or controlled:(2) Derivatives (other thanoptions):(3) Options and agreements topurchase/sell:TOTAL: 20,580,092 9.83 0 0.0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchaseor sell relevant securities, should be given on a Supplemental Form 8 (OpenPositions).

(b) Rights to subscribe for new securities (including directors' and otherexecutive options)

Class of relevant security in N/Arelation to which subscription rightexists:Details, including nature of the N/Arights concerned and relevantpercentages:

If there are positions or rights to subscribe to disclose in more than oneclass of relevant securities of the offeror or offeree named in 1(c), copytable 2(a) or (b) (as appropriate) for each additional class of relevantsecurity.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities Ordinary Shares Sale 4,000,000 0.7812p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description reference unit security e.g. opening/closing a securities e.g. CFD long/short position, increasing/reducing a long/short position N/A

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Optionrelevant description purchasing, securities price

date moneysecurity e.g. call selling, to which per unit e.g. paid/ option varying option American, received etc. relates European per unit etc. N/A(ii) Exercising Class of relevant Product Number of Exercise price per security description securities unit e.g. call optionN/A

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit

security (if applicable) e.g. subscription, conversion N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities ofthe offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (asappropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement orunderstanding, formal or informal, relating to relevant securities which maybe an inducement to deal or refrain from dealing entered into by the personmaking the disclosure and any party to the offer or any person acting inconcert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options orderivatives

Details of any agreement, arrangement or understanding, formal or informal,between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevantsecurities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None(c) AttachmentsIs a Supplemental Form 8 (Open Positions) attached? Y/N NODate of disclosure: 20 February 2013Contact name: David Holland, for Aberforth Partners LLPTelephone number: 0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a RegulatoryInformation Service and must also be emailed to the Takeover Panel atmonitoring@disclosure.org.uk . The Panel's Market Surveillance Unit isavailable for consultation in relation to the Code's dealing disclosurerequirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Date   Source Headline
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
6th Sep 201312:54 pmRNSHolding(s) in Company
4th Sep 20134:40 pmRNSSecond Price Monitoring Extn
4th Sep 20134:35 pmRNSPrice Monitoring Extension
2nd Sep 201312:00 pmRNSHolding(s) in Company
29th Aug 20134:41 pmRNSSecond Price Monitoring Extn
29th Aug 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20139:00 amRNSHalf Yearly Report
16th Aug 20134:40 pmRNSSecond Price Monitoring Extn
16th Aug 20134:35 pmRNSPrice Monitoring Extension
15th Aug 20135:32 pmRNSHolding(s) in Company
14th Aug 20134:56 pmRNSHolding(s) in Company
30th Jul 20134:40 pmRNSSecond Price Monitoring Extn
30th Jul 20134:35 pmRNSPrice Monitoring Extension
23rd Jul 20133:44 pmRNSHolding(s) in Company
9th Jul 20132:00 pmRNSCompany Update
8th Jul 20134:40 pmRNSSecond Price Monitoring Extn
8th Jul 20134:35 pmRNSPrice Monitoring Extension
5th Jul 201310:48 amRNSHolding(s) in Company
5th Jul 20137:00 amRNSCompany Update
27th Jun 20134:40 pmRNSSecond Price Monitoring Extn
27th Jun 20134:35 pmRNSPrice Monitoring Extension
25th Jun 20132:05 pmRNSResults of Annual General Meeting
14th Jun 20134:40 pmRNSSecond Price Monitoring Extn
14th Jun 20134:35 pmRNSPrice Monitoring Extension
4th Jun 20132:48 pmRNSBlocklisting Six Monthly Return
24th May 20134:40 pmRNSSecond Price Monitoring Extn
24th May 20134:35 pmRNSPrice Monitoring Extension
17th May 20137:00 amRNSInterim Management Statement
16th May 20131:20 pmRNSHolding(s) in Company
8th May 20136:09 pmRNSHolding(s) in Company
8th May 20135:47 pmRNSHolding(s) in Company
2nd May 20131:45 pmRNSHolding(s) in Company
1st May 20134:35 pmRNSPrice Monitoring Extension
30th Apr 20137:00 amRNSFinal Results
26th Apr 20134:50 pmRNSHolding(s) in Company
24th Apr 20133:47 pmRNSHolding(s) in Company
26th Mar 20134:40 pmRNSSecond Price Monitoring Extn
26th Mar 20134:35 pmRNSPrice Monitoring Extension
22nd Mar 201311:50 amRNSHolding(s) in Company
20th Mar 20131:15 pmRNSHolding(s) in Company
19th Mar 201311:34 amRNSForm 8.3 - Ark Therapeutics
19th Mar 20139:47 amRNSHolding(s) in Company
18th Mar 20131:54 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Mar 201312:01 pmRNSTermination of Offer Period and Rule 10.8 Waiver
7th Mar 20134:22 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 20133:04 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 201310:02 amRNSForm 8.3 - Ark Therapeutics Group Plc
1st Mar 201311:49 amRNSForm 8.3 - Ark Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.